TaiRx, Inc.（TPEX：6580）is a pharmaceutical company focusing on the development of novel therapeutics targeting on cancer as first priority. Our team has extensive experiences in new drug development, which allows us to expedite the development process going from early stage to IND/NDA approval. Our drug portfolio covers new chemical entity, biological drug, and new formulation design in order to promptly find cures for severe diseases and make improvements on current standard treatments.
The products currently in development and on the market:
1. CVM-1118, a novel oral cancer drug in phase II clinical trials for HCC and neuroendocrine tumor.
2. TRX-920, a novel oral formulation of SN38 preparing for IND submission.
3. Zelnite®, an approved drug for the treatment or prevention of selenium deficiency.